Experimental cell therapy takes on Drug-Resistant melanoma
NCT ID NCT06708455
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests a new cell therapy called RAPA-201 for people with advanced melanoma that has stopped responding to PD-(L)1 inhibitors. The therapy uses a patient's own immune cells, modified to resist the drug rapamycin, and is given along with chemotherapy. The study aims to see if this combination can shrink tumors and improve outcomes in 65 participants with stage IIIc or IV melanoma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RAPA-201 (a type of immune cell therapy made from the patient's own cells, designed to resist the drug rapamycin) plus chemotherapy (carboplatin and paclitaxel)
What this could lead to
If successful, this could offer a new treatment option for people with advanced melanoma that no longer responds to standard immunotherapy.
What could go wrong
This is an early Phase 2 trial with only 65 people, so results may not apply to everyone. The treatment involves strong chemotherapy and cell therapy, which can cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••